相关实验视频

Updated: Jul 11, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

挑战与机遇并存:在癌症治疗中PD-L1的空间异质表达

Yazhen Wang^1,2, Yang Zhou², Lianyi Yang¹

¹National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, P. R. China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|November 7, 2023

概括

编程死亡配体1 (PD-L1) 抗体在癌症免疫治疗中表现有前途,但由于PD-L1而面临局限性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

反编程死亡配体1 (PD-L1) 抗体被用于癌症免疫疗法.
局限性包括自身免疫,瘤超级进展和低患者应答率.
PD-L1在瘤 (膜,细胞质,细胞核,外体) 中表现异质,影响治疗疗效.

研究的目的:

介绍PD-L1.1.的空间异质表达的概念.
分析调节PD-L1.1的分子机制.
确定PD-L1导向癌症治疗的潜在治疗点和新策略.

主要方法:

对PD-L1表达和功能的现有文献进行审查和分析.
探索PD-L1.1.的监管机制.
目前治疗剂的概述和小分子调节器的发展.

主要成果:

在瘤中,PD-L1的表达在空间上是异质的.
了解这些机制可以提高PD-L1抗体的有效性.
新的治疗点和小分子调节器正在开发中.

结论:

PD-L1的空间异质性是限制当前免疫疗法的关键因素.
针对各种PD-L1形式和调节机制提供了一个有前途的治疗途径.
小分子调节器代表了增强基于PD-L1的癌症治疗的新策略.

关键词:

在PD-L1中.癌症治疗方法癌症治疗方法监管机制监管机制小分子调节器的小分子调节器空间异质性空间异质性

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...